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Abstract Many psychiatric disorders, like schizophrenia,
affective disorders, addictions and different forms of
dementia are associated with sleep disturbances. In the
etiology and course of those diseases inflammatory pro-
cesses are regarded to be an increasingly important factor.
They are also a frequently discussed element of the
pathology of sleep. In this literature review reports on
correlations between poor sleep and inflammatory respon-
ses in various psychiatric conditions are discussed. The link
between schizophrenia, affective disorders and inflamma-
tory cytokines is a complex phenomenon, which has been
already confirmed in a number of studies. However, the
presence of sleep deficits in those conditions, being a
common symptom of depression and psychoses, can be an
additional factor having a considerable impact on the
immunological processes in mental illnesses. In the ana-
lyzed data, a number of studies are presented describing the
role of inflammatory markers in sleep disturbances and
psychopathological symptoms of affective, psychotic,
neurogenerative and other disorders. Also attention is
drawn to possible implications for their treatment. Efforts
to use, e.g., anti-inflammatory agents in psychiatry in the
context of their impact on sleep are reported. The aspect of
inflammatory markers in the role of sleep deprivation as the
treatment method in major depressive disorder is also
discussed. A general conclusion is drawn that the
improvement of sleep quality plays a crucial role in the
care for psychiatric patients.
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Introduction
The correlation between sleep quality and immunological
processes has been confirmed in a number of research reports
(Kapsimalis et al. 2005; Krueger 2008; Krueger et al. 2011;
Weschenfelder et al. 2012; Zeitzer 2013). The changes in the
activity of inflammatory factors in related sleep disorders
may be linked to the functioning of the central nervous
system (Wisor et al. 2011; Zhu et al. 2012; Kang et al. 2013;
Zielinski et al. 2014). Appropriate length and quality of sleep
is a commonly discussed lifestyle factor affecting the func-
tioning of healthy subjects, and the role it plays in the course
of various psychopathological conditions is meaningful
(Prather et al. 2009). The correlation between sleep distur-
bances and immunological changes, which may affect the
brain functioning seems to have a key impact on the devel-
opment and course of different psychiatric disorders (Illi
et al. 2012; Voderholzer et al. 2012) as well as of comorbid
conditions, which may occur (Wichniak and Jarema 2012).
The link between depression or schizophrenia and inflam-
matory cytokines is a complex phenomenon, which has been
already confirmed in a number of studies (Khandaker et al.
2014; Maes et al. 1995; Potvin et al. 2008; Drexhage et al.
2010; Miller et al. 2011), which provide evidence indicating
that increased levels of pro-inflammatory cytokines play an
important role in the etiology of schizophrenia and depres-
sion. However, the presence of sleep disturbances in those
conditions, being a common symptom of the syndromes of
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depression and psychoses, can be an additional factor having
a considerable impact on the immunological processes in
psychiatric disorders.
The aim of this literature analysis is to find out the
correlation between sleep disturbances, inflammatory pro-
cesses and mental conditions like affective disorders,
schizophrenia, addictions, dementia and other psychiatric
disorders.
Methods
The focus of this review was on studies on sleep, psychi-
atric disorders and inflammatory processes (1970–2014).
We searched PubMed using the following search terms
(effective date: 1st August 2015): (sleep (Title/Abstract)
AND psychiatric disorders (Title/Abstract) OR depression
(Title/Abstract) OR schizophrenia (Title/Abstract) OR
addiction (Title/Abstract) OR dementia AND inflammatory
processes (Title/Abstract) OR cytokine (Title/Abstract) OR
interleukin OR tnf OR prostaglandins OR immune system
AND English (lang) AND: 2015/08/01(PDAT)).
Results
We retrieved 38 results from our PubMed search. We drew
our attention mainly to those of them, which were original
study papers devoted to groups of patients suffering from
schizophrenia, depression, addictions, dementia, reaction to
severe stress, adjustment disorders and psychosomatic
disorders complicated by serious sleep disturbances, and in
which the analysis of inflammatory markers was taken into
consideration. Finally we found ten papers matching our
criteria, which are listed and summarized in Table 1. Those
papers differed in terms of study designs and methodology,
with the inclusion of various clinical study groups with the
number of participants within a range from 14 to 95. The
most common markers evaluated in those studies were IL-
1b, IL-6, IL-10, Prostaglandin D2, E2, F2a, corticotropin,
IFN-gamma, NK cells, and TNF.
Some other papers were either reviews, like the works of
Ritter et al. (2013), Motivala et al. (2011) or referred to
wider phenomena concerning inflammation processes and
psychiatric disorders, anyway they also supported our
discussion.
Discussion
Sleep, depression and cytokines
Brain, belonging to cytokine regulatory pathways, regu-
lates the leukocyte action via autonomic nerves and
neuroendocrine hormones (Besedovsky et al., 1983). Some
cytokines like IL-1 are produced by astrocytes and
microglia cells (Merill 1992) and the increased IL-1 level
in the blood of depressive patients has been confirmed. IL-
1 in CNS is known to be responsible for psychomotor
retardation. Moreover, there are findings, suggesting that
increased secretion of IL-6 is involved in the pathogenesis
of depression. The increased level of IL-6 has been shown
in patients with depressive disorder (Maes et al. 1995) and
it probably influences the metabolism of serotonin in CNS,
decreasing the availability of tryptophan in the blood
(Fernstrom and Faller 1978). Many authors conclude that
cytokine pathways are responsible for mutual influence of
poor sleep and inflammatory cytokines (Meier-Ewert et al.
2004, Irwin et al. 2006). Accumulative evidence suggests
cross relations between sleep, depression and disturbances
of inflammatory system.
Recently, two main streams of studies are distinguished.
One focuses on the relation between mechanisms of sleep
and inflammatory processes by examining the influence of
induced sleep disturbances on inflammatory markers. It is
proven that total sleep deprivation induces the changes in
inflammatory markers, which suggests the relation between
sleep and inflammatory cytokines. Two findings are
observed: the increase of CRP in total sleep deprivation, and
the increase of IL-6 in longer periods of partial sleep depri-
vation (Meier-Ewert et al. 2004; Vgontzas et al. 2004). This
pattern of changes in inflammatory markers occurs only if
the sleep deprivation lasts longer than one night. In shorter
human experiments the results were not so consistent (re-
viewed in Motivala 2011). However, even 1 day of partial
sleep deprivation produces many short lasting disturbances
in immunity, like reduction of activity of natural killers and
lymphokine-activated killers or the suppression of IL-2
production (Irwin et al. 2006). The important implication
from human studies is that adequate sleep period shortens the
time of viral infection (Cohen et al. 2009). Due to the mea-
surement difficulties, studies of another inflammatory
cytokines like TNFa and IL-1b are inconsistent (reviewed in
Motivala 2011). New studies reveal the relation between
circadian rhythm and immunological system activity
(Porkka-Heiskanen et al. 2013). Going further, loss of sleep
triggers the genetic mechanism of transcription of genes
related to immunity (Moller-Levet et al. 2013).
The other approach identifies the connection between
sleep and inflammatory processes in observation of how
inflammatory cytokines behave in insomnia. It was
reviewed by Motivala (2011) that chronic sleep distur-
bances lead to elevation of inflammatory cytokines like IL-
6, CRP and TNFa. The authors indicate no clear evidence
that insomnia is the only reason of inflammatory cytokines
disturbances and the importance of more thorough analysis
of comorbidity in the future studies.
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Because of the high prevalence of poor sleep in
depressive patients (90 %) the sleep disturbances may link
depression with the increase of inflammatory cytokines.
Prather et al. (2009) gave interferon alpha (IFNa) to the
non-depressive patients with hepatitis C. He observed
major depression in 22 % of 95 patients as well as the
significant decrease of the sleep quality (Prather et al.
2009). Statistical analysis revealed the time sequence of the
observed phenomena. The higher pre-treated blood con-
centration of IL-6 was the risk factor of the development of
major depressive disorder but sleep disturbances was fol-
lowed by depressive symptoms. One of the most important
conclusions from the study is that inflammatory markers
disrupt sleep and only then disturbed sleep results in
depressive symptoms (Buysse et al. 2008). The conclusion
is consistent with the previous findings of Motivala et al.
(2005) who showed that sleep disturbances evoke the
increase of IL-6 and soluble intercellular adhesion mole-
cule, and that the depression relates to the problems with
the initiation of sleep (Motivala et al. 2005). The described
phenomena are present not only in major depression, but
also in other affective disorders. According to Ritter et al.
(2013) changes observed in the sleep of patients with
bipolar disorder are also related to the elevation of IL-6.
Most recent extensive meta-analysis of Howren and
colleagues (2009) aimed at finding the positive relation
between depression and inflammatory markers in scientific
papers published from January 1967 to January 2008
(Howren et al. 2009). The authors concluded that there is a
positive correlation between depression and the increase of
the three inflammatory cytokines: CRP, IL-1 and IL-6.
More importantly, the revealed associations are not related
to medication, age or gender of the patient. Another
research, done by a Canadian group found changes in
levels of serotonin, pro-inflammatory cytokines, brain-
derived neurotrophic factor (BDNF) and other transmitters
in comorbid chronic pain, depression and sleep disruption
(Boakye et al. 2015). The presence of a correlation between
cytokines level and depressive symptoms may justify the
proposal of the new type of depression called inflammatory
cytokine-associated depression (ICAD) (Lotrich 2015).
Another aberration of immunity in depressive patients is
aforementioned disturbed natural killers’ (NK) activity. In
depressed patients a bigger severity of insomnia correlates
with lower NK activity (Irwin 2002). More importantly, the
disturbed NK function does not relate to any other
depressive symptom. Similar pattern of disturbance was
found in non-depressed insomnia suffering subjects, which
Table 1 Studies on inflammatory markers in schizophrenia, depression, addictions, dementia, reaction to severe stress, adjustment disorders and
psychosomatic disorders complicated sleep disturbances
Authors (year) Study group Inflammatory factor Conclusions
Prather et al.
(2009)
95 non-depressed hepatitis C
patients
IFN-alpha, IL-6 High levels of inflammation and poor sleep quality




22 patients with depressive
disorder
IL-6, sICAM, MCP-1, IL-6sR Nocturnal elevations of IL-6 and sICAM associated
with sleep disturbance in depressed patients
Appelberg et al.
(1997)
20 drug-free patients with acute
non-affective psychoses
IL-1b in plasma Negative correlation between IL-1b and the length
of sleep period and of REM sleep






Prostaglandin D2, E2, F2a and
corticotropin releasing factor
in cerebrospinal fluid




45 women and 38 men aged
50 years and older undergoing
acute stress
IL-6 Poor sleepers had significantly larger IL-6 responses
to the cognitive stressors than good sleepers
Von Ka¨nel et al.
(2006)
64 older caregivers of people with
AD
IL-6, D-dimer Poor sleep was associated with higher plasma IL-6
and D-dimer levels
Chen et al. (2012) 43 drug-free AD patients IL-1b and TNF-a Daytime sleepiness in mild and moderate AD




24 alcoholic patients IFN-gamma, IL-10, IL-6, NK
cells
Disordered sleep contributes to immune alterations
in patients with chronic alcoholism
Irwin et al.
(2004)
16 abstinent African American
alcoholics
IL-6 and TNF Circulating levels of proinflammatory cytokines
may have a negative influence on sleep initiation
Heffner et al.
(2011)
25 adults with chronic low back
pain
IL-6 In adults with chronic low back pain poorer sleep
quality was associated with higher IL-6 levels
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implies strong relation between immunity and sleep but not
with depression itself (Irwin 2002).
Inflammatory factors and sleep disturbances
in schizophrenia
Sleep disturbances, although seldom reported as a pre-
dominant complaint, are one of the hallmarks of
schizophrenia. Disturbed sleep is estimated to occur in
30–80 % of people with schizophrenia, depending on the
degree of psychotic symptomatology (Cohrs 2008). The
main polysomnographic features in schizophrenia are:
reduced sleep efficiency; decreased total sleep time;
shortened slow wave sleep, REMOL (rapid eye movement
sleep onset latency) and REM (rapid eye movement) sleep;
increased sleep onset latency and longer wake time after
sleep onset (Monti et al. 2013). According to a case–
control study by Wullf and colleagues (2012), delayed
sleep onset latency, disturbance of sleep maintenance and
prolonged time awake are characteristics for schizophrenic
patients regardless of either their medication status (drug-
naive or drug-treated) or the phase of the clinical course
(acutely psychotic or clinically stable). Sleep disturbances
observed in schizophrenic patients could be partially
related to the hyperactivity of the dopaminergic system
(Monti et al. 2013). Although there is a general consensus
that the dopaminergic neurotransmission is involved in the
pathophysiology of schizophrenia, the role of the inflam-
matory process in the pathogenesis of schizophrenia has
been discussed since almost a century (Dameshek 1930). A
growing body of evidence indicates increased levels of
pro-inflammatory cytokines in schizophrenia patients
(Potvin et al. 2008; Drexhage et al. 2010; Miller et al.
2011). Among them, IL-6, IL-10 and TNFa (Cazullo et al.
1998; Kunz et al. 2011; Miller et al. 2011) gained special
research attention. It was observed that the serum levels of
IL-2 and IL-6 are increased in first episode drug-naı¨ve
patients with psychosis (Petrikis et al. 2015), and that IL-3
levels are significantly increased in patients with chronic
schizophrenia (Xiu et al. 2015). Brazilian authors go far
enough in their analyses to postulate that the combination
of five biomarkers (sTNF-R1, sTNF-R2, CCL11, IP-10,
IL-4) may predict the diagnosis of SCZ with a sensitivity
of 70.0 % and a specificity of 89.4 % (Noto et al. 2015).
According to the Australian group there can be a subtype
of schizophrenia including patients displaying poor verbal
fluency and reduced Broca’s area volume, in whom the IL-
1b mRNA cytokine level is elevated (Fillman et al. 2015).
On a different note, maternal prenatal infections were
found to increase the risk of schizophrenia, regardless of
the pathogen (Brown and Derkits 2010). Neuroinflamma-
tion during early fetal development caused by exposure to
cytokine-releasing agents may be pathophysiologically
relevant to the progression of schizophrenia (Meyer et al.
2011). Additionally, associations were found between
schizophrenia and inflammation-related gene regions. In a
genome-wide association study (Shi et al. 2009) most
probable susceptibility genes were identified in a region on
chromosome 6p22.1, which includes a histone gene cluster
and several immunity-related genes. Hence, the question
emerges whether any evident link could be found between
inflammatory factors and sleep disturbances in
schizophrenia. Appelberg et al. (1997) performed
polysomnography and measured morning IL-1b plasma
values in 20 drug-free patients with acute non-affective
psychoses (10 diagnosed with schizophrenia, 5 with delu-
sional disorder and 5 with atypical psychosis). The authors
found that the length of sleep period and the relative time
of REM sleep correlated negatively with IL-1b levels.
There was also a positive correlation between REM
latency and IL-1b levels. Another study (Nishino et al.
1998) was aimed to shed a light on the role of corticotropin
releasing factor (CRF) and prostaglandins (PGs) in the
pathophysiology of sleep disturbances observed in
schizophrenia. The study hypothesis was based on findings
of previous studies, in which both CRF (Ehlers et al. 1986;
Opp et al. 1989) and PGs (Hayaishi 1991; Matsumura et al.
1994) were reported to modulate sleep in experimental
animals. To test that hypothesis, the authors carried out
polysomnographic recordings and measured the cere-
brospinal fluid levels of PGD2, PGE2, PGF2a and CRF in
14 unmedicated schizophrenic patients and 14 healthy
controls. However, the results were not in favor of authors’
assumptions—neither group differences in cerebrospinal
CRF and PG levels, nor correlations between CSF vari-
ables and sleep parameters were reported. Melatonin
comprises an indirect link between sleep disturbances and
inflammation in schizophrenia. Hypnotic and circadian
rhythm resynchronizing features of melatonin are widely
acknowledged. Nevertheless, it is noteworthy that mela-
tonin is additionally involved in immunomodulation
(Maldonado et al. 2009), attenuates pro-inflammatory
cytokines and other inflammatory mediators, and is acting
as a free radical scavenger (Esposito and Cuzzocrea 2010).
Melatonin was found to be an important factor in the eti-
ology, pathogenesis and treatment of schizophrenia (for
review, see Anderson and Maes 2012). Accumulating
evidence indicates reduced levels in patients with
schizophrenia, regardless of the treatment status (Mon-
teleone et al. 1992, 1997; Bersani et al. 2003). A case–
control study conducted among monozygotic twins dis-
cordant for schizophrenia reported significant group dif-
ferences in levels of melatonin (Afonso et al. 2010). The
question whether melatonin alterations are closely related
to immunological changes observed in schizophrenic
subjects still remains open.
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Inflammatory factors and sleep disturbances
in other psychiatric disorders
The literature referring to the problem of inflammatory
disturbances in sleep disorders other than depression and
schizophrenia is not very rich; however, some interesting
observations are available. Inflammatory responses to sleep
disorders can be found for example in patients undergoing
acute stress, even generally healthy. An interesting study
relating to this group was performed by Heffner et al.
(2012) on men and women aged 50 and older. The patients
with sleep disorders were examined with a series of com-
plex cognitive tests, and it turned out that they had sig-
nificantly larger IL-6 responses to the cognitive stressors in
comparison with participants with no reported sleep prob-
lems. The authors raised a conclusion that older adults may
present vulnerability specific to changes in sleep and
inflammatory regulation related to age. A similar phe-
nomenon can be observed among caregivers of patients
suffering from dementia. Von Ka¨nel et al. (2006) attempted
to determine the correlation between sleep measures and
plasma levels of cytokine interleukin (IL-6) and the pro-
coagulant marker fibrin D-dimer in those group of people.
The results showed that this correlation was positive,
especially in caregivers of patients with Alzheimer’s dis-
ease. The above problem was raised also by Mills et al.
(2009). Their study examined the effects of caregiver
gender and severity of the spouse’s dementia on sleep,
coagulation, and inflammation in the caregiver. The results
of their study suggested that males, who take care of
spouses with more severe dementia experience more dis-
turbed sleep and have increased coagulation processes.
This phenomenon was associated with disturbed sleep.
Inflammatory responses to sleep deficits can also be present
in the patients suffering from dementia themselves. Chen
et al. (2012) performed a study aimed to examine
whether sleep disturbance in a cohort of patients with
mild/moderate Alzheimer’s disease was associated with
serum levels of IL-1b and TNF-a. The results indicated
that that daytime sleepiness in mild and moderate AD
patients is associated with elevation of serum TNF-a
concentrations.
Another interesting group of patients among whom
sleep disorders may lead to changes in inflammatory fac-
tors are patients with addiction. Redwine et al. (2003)
examined the relationships between sleep, nocturnal
expression of immunoregulatory cytokines, and natural
killer (NK) cell activity in alcoholic patients as compared
with control subjects. Alcoholic patients showed lower
levels of IL-6 production, suppression of the IL-6/IL-10
ratio, and a reduction of NK cell activity, coupled with
losses of delta sleep and increases of rapid eye movement
sleep, as compared with control subjects, which led to a
conclusion that disordered sleep contributes to immune
alterations in patients with chronic alcoholism. Irwin et al.
(2004) examined abstinent African American alcoholics.
Prolonged sleep latency and increased rapid eye movement
sleep in those patients was correlated with the elevations of
IL-6 and TNF as compared to controls after adjustment for
alcohol consumption and body mass index. As a result of
sleep deprivation, patients addicted to alcohol showed
greater nocturnal levels of IL-6 and greater nocturnal
increases of TNF in comparison with control group mem-
bers. The authors concluded that that circulating levels of
proinflammatory cytokines may have a negative influence
on sleep initiation. Changes in inflammatory factors can be
found also among patients with psychosomatic disorders.
Ali and Orr (2014) report that there is an association of
sleep disturbances with the disease activity, subclinical
inflammation, and risk of disease relapse in inflammatory
bowel disease. Heffner et al. (2011) performed a study, the
objective of which was to examine associations between
sleep disturbance and interleukin-6 (IL-6), in patients with
and without chronic low back pain. It turned out that they
had more sleep disturbance than the members of the control
group, suggesting that inflammatory processes may play a
significant role in the cycles of pain and sleep disturbance.
The authors expressed their hope that clinical interventions
improving sleep and reducing coexisting inflammatory
dysregulation could improve chronic pain management.
Conclusions and implications for new treatment
options
The above analysis of literature data shows that a link can
be found between psychiatric disorders, sleep and inflam-
matory processes. This link is important for further
research on the etiology of mental illnesses, but may also
turn out to be useful in new future treatment strategies, e.g.,
anti-inflammatory agents may possibly be useful both in
sleep disorders, and in mental illnesses. An interesting
study was performed on mice undergoing sleep depriva-
tion, treated with minocycline. This treatment strategy
showed to have an impact on sleep architecture; however,
the authors did not discover the underlying mechanism
(Wisor et al. 2011). Attempts are made to use minocycline
in affective disorders. Miyaoka et al. (2012) in their
6-week, open-label study found out that minocycline in
combination with antidepressants is effective and well
tolerated in the treatment of unipolar psychotic depression.
Chaudhry et al. (2012) observed a positive effect of
minocycline on symptoms of schizophrenia. Also other
research projects were carried out in this field (Dean et al.
2012; Savitz et al. 2012; Berk et al. 2013; Jhamnani et al.
2013; Fond et al. 2014). The above results suggest that
anti-inflammatory agents could be useful in the treatment
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of both sleep disorders, and such psychiatric conditions like
depression or schizophrenia, being useful also in situations,
when these conditions are combined. In this context it is
also important to evaluate how sleep deprivation, which is
used as one of treatment options in major depressive dis-
order, affects inflammatory processes. This problem was
widely discussed in the paper by Voderholzer et al. (2012).
According to the authors sleep deprivation affect cytokine
levels in both depressed patients and healthy subjects, but
does it in different ways. In depressed patients IL-6 levels
are normalized during the recovery night, after earlier
increase. The treatment proposals, which were mentioned
above may turn out to be advantageous for patients suf-
fering from psychiatric disorders with additional sleep
disturbances; however, still more researches are necessary
to conform their efficacy. Anyway it should be important
for clinicians, that the improvement of sleep quality may be
a key factor in the process of treatment of these diseases.
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